Galderma Jumps Into Dermal Filler Device Market With Q-Med Offer
This article was originally published in The Gray Sheet
Executive Summary
Dermatology drug maker Galderma will be able to offer Q-Med’s Restylane dermal filler device alongside its Azzalure botulinum toxin for wrinkle treatment after acquiring Q-Med for up to $1.1 billion.
You may also be interested in...
Valeant Gains Medicis Through $2.6 Billion Acquisition
The deal is mostly pharmaceutical focused, but Medicis sells several injectable dermal filler devices, including Restylane and Perlane.
FDA Panel Strongly Endorses Oceana's Solesta Fecal Incontinence Product
An FDA advisory panel offered strong support Dec. 2 to Ocean Therapeutics' effort to win PMA approval for its Solesta injectable bulking agent for fecal incontinence.
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4